A Clinical Study of ONO-1110 in Patients With Hunner Type Interstitial Cystitis
NCT ID: NCT06752603
Last Updated: 2025-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
50 participants
INTERVENTIONAL
2025-04-02
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ONO-1110
ONO-1110 tablets once a day
ONO-1110
ONO-1110 tablets once a day
Placebo
Placebo tablets once daily
Placebo
Placebo tablets once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ONO-1110
ONO-1110 tablets once a day
Placebo
Placebo tablets once daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age (at the time of informed consent): 18 years and older
* Outpatient
* Patients who are considered capable of understanding the study procedures and completing the pain diary, bladder diary, and questionnaires appropriately by the investigator (sub-investigator）
* Patients given a diagnosis of HIC by cystoscopy
* Patients with chronic pelvic pain involving the bladder and lower urinary tract symptoms such as increased micturition and pollakiuria
Exclusion Criteria
* Patients with a history of bladder augmentation or radical cystectomy
* Patients with pain other than HIC that may affect assessments in this study
* Patients with a past history of or concurrent neurologic diseases that may affect assessments in this study
* Patients receiving medications for psychiatric disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ono Pharmaceutical Co. Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Project Leader
Role: STUDY_DIRECTOR
Ono Pharmaceutical Co. Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nagoya University Hospital
Nagoya, Aichi-ken, Japan
Harasanshin Hospital
Fukuoka, Fukuoka, Japan
Fukushima Medical University Hospital
Fukushima, Fukushima, Japan
Japanese Red Cross Gifu Hospital
Gifu, Gifu, Japan
Kurosawa Hospital Health Park Clinic
Takasaki, Gunma, Japan
Niimura Hospital
Kagoshima, Kagoshima-ken, Japan
Kanto Rosai Hospital
Kawasaki, Kanagawa, Japan
Rakuwakai Marutamachi Hospital
Kyoto, Kyoto, Japan
Ueda Clinic
Kyoto, Kyoto, Japan
Izumi Chuo Hospital
Sendai, Miyagi, Japan
Shinshu University Hospital
Matsumoto, Nagano, Japan
Nakamura Hospital
Beppu, Oita Prefecture, Japan
Okayama University Hospital
Okayama, Okayama-ken, Japan
Nanri Urological Clinic
Saga, Saga-ken, Japan
The Jikei University Hospital
Minato-Ku, Tokyo, Japan
Kyorin University Hospital
Mitaka, Tokyo, Japan
The University Of Tokyo Hospital
Tokyo, Tokyo, Japan
Toyama Rosai Hospital
Uozu, Toyama, Japan
University Of Yamanashi Hospital
Chūō, Yamanashi, Japan
Nagasaki University Hospital
Nagasaki, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
North America Clinical Trial Support Desk
Role: CONTACT
Phone: +18665877745(Toll-Free)
Email: [email protected]
International Clinical Trial Support Desk
Role: CONTACT
Phone: +17162141777(Standard)
Email: [email protected]
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
jRCT2031240558
Identifier Type: REGISTRY
Identifier Source: secondary_id
ONO-1110-06
Identifier Type: -
Identifier Source: org_study_id